Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin + CHEP in Previously Untreated CD30-expressing PTCL
2024-511567-28-01Phase 2Authorised
- Sponsor
- Kooperativní lymfomová skupina
- Start
- Aug 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brentuximab vedotin in peripheral T-cell lymphoma (PTCL), systemic anaplastic large cell lymphoma (ALCL), peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) and 8 more, sponsored by Kooperativní lymfomová skupina. Primary endpoint: PET-negative complete response rate at end of treatment. Planned start Aug 2024; status: authorised.
02
Drugs
brentuximab vedotin
03
Conditions
peripheral T-cell lymphoma (PTCL)systemic anaplastic large cell lymphoma (ALCL)peripheral T-cell lymphoma not otherwise specified (PTCL-NOS)angioimmunoblastic T-cell lymphoma (AITL)adult T-cell leukemia-lymphoma (ATLL)
Beyond the preview
Go deeper on 2024-511567-28-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511567-28-01.